View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 14, 2021

Immusoft and Takeda to develop cell therapies for rare metabolic disorders

The collaboration will focus on developing protein therapies that can be delivered across the blood-brain barrier.

Immusoft has signed a research and licensing agreement with Takeda Pharmaceutical for cell therapies in rare inherited metabolic disorders that lead to complications in the central nervous system (CNS).

The collaboration will see the discovery, development and commercialisation of cell therapies.

The cell therapies will be developed using Immusoft’s Immune System Programming (ISP) technology platform.

This ISP platform changes the B cells of a patient and instructs the cells to produce gene-encoded therapies.

This partnership is aimed at providing protein therapies across the blood-brain barrier.

Founded in 2009, Immusoft is also developing new approaches to modify cell therapies to be more durable and redosable.

Immusoft CEO Sean Ainsworth said: “This advances our leadership position in B cells as biofactories for therapeutic protein delivery, a novel approach that Immusoft has pioneered.

“This partnership provides Immusoft with significant resources to further develop our Immune System Programming (ISP) technology platform and therapies in diseases for which patients have limited options.”

Under the deal, the company will receive an undisclosed upfront payment as well as research funding support from Takeda.

It is also entitled to get future option fees and milestone payments,  with a total potential value of over $900m in case all options are exercised and milestones are reached.

According to the agreement, Takeda has options to exclusively license programmes at the pre-clinical stage while Immusoft is entitled to get tiered royalties on commercial products developed from the partnership.

Additionally, Takeda will handle the preclinical and clinical development, as well as the commercialisation of the products.

Takeda Rare Diseases Drug Discovery Unit head Madhu Natarajan said: “We continue to build our internal capabilities, as well as partner with innovative companies early on in the discovery process to advance our next-generation gene and cell therapy ambitions for rare genetic and hematologic diseases.

“Working together with Immusoft, we hope to validate their ISP technology for CNS delivery of innovative therapeutics for rare neurometabolic diseases.”

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology